ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 926

Methotrexate Is Associated with Reduced Cardiovascular Risk in Rheumatoid Arthritis Independent of Disease Activity Modification

Tate Johnson1, Joshua Baker 2, Punyasha Roul 1, Harlan Sayles 1, Grant Cannon 3, Brian Sauer 3, Ted Mikuls 4 and Bryant England 5, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, 4VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, 5VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: cardiovascular disease and methotrexate (MTX), Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Session Title: 3S108: RA – Diagnosis, Manifestations, & Outcomes II: Cardiovascular Comorbidities (921–926)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of cardiovascular disease (CVD). Methotrexate (MTX), a mainstay in the treatment of RA, appears to mitigate this risk. However, prior studies have been limited in their ability to account for the effects of disease activity and examine the mechanisms that account for CVD risk reduction. We aimed to determine whether the association of MTX with reduced CVD risk was related to modulation of disease activity or direct effects.

Methods: We observed participants in a prospective, multicenter cohort of US Veterans with RA for incident CVD events from 4/2005 to 4/2015. CVD events were defined as a composite of acute myocardial infarction (AMI), coronary revascularization, stroke, and hospitalization for heart failure (CHF). These were identified using diagnostic and procedure codes from inpatient and outpatient encounters (validated by medical record review) and the National Death Index. Demographics, traditional CVD risk factors, comorbidities (including hypertension, hyperlipidemia, diabetes, chronic kidney disease, liver disease, and prior CVD), as well as aspirin, statin, and NSAID use were assessed using registry and administrative data. MTX (and other DMARD/prednisone) exposure was defined at each visit by linking to pharmacy dispensing data, including a 90-day grace period upon discontinuation. To reduce confounding by disease activity, we used marginal structural models incorporating disease activity from the prior visit into the propensity to receive MTX to determine the overall association of MTX with CVD events. To examine whether the association of MTX use with CVD was mediated through disease activity, we used sequential Cox models including post-MTX disease activity.

Results: RA patients (n=2168) were predominantly older (mean age 64 years), male (90%), frequent smokers (80% current/former), seropositive (79% RF, 78% anti-CCP), with moderate baseline disease activity (mean DAS28 3.7). The incidence of composite CVD events (n=401) was lower in MTX exposed patients (33.8/1000 person-years) vs. MTX non-exposed patients (40.7/1000 person-years). Using marginal structural models to account for disease activity at the prior visit, MTX use was associated with reduced risk of composite CVD events (HR 0.72, 95% CI 0.55-0.89) and CHF (HR 0.40, 95% CI 0.23-0.67), with a trend toward reduced risk of AMI and stroke (Table). In sequential multivariable Cox models to assess direct and indirect effects, adjustment for post-MTX disease activity did not significantly alter the association of MTX use with composite or individual CVD events (range ΔHR -0.03 to 0.01, Figure).

Conclusion: In a multicenter RA cohort, MTX use was associated with a 30% reduced risk of composite CVD events and a 60% reduced risk of CHF hospitalizations. The protective effect of MTX was independent of other factors including treatment-related changes in disease activity, suggesting that additional mechanisms mediate CVD risk reduction with MTX in RA. This should be considered when selecting DMARD therapy regimens in RA patients.


Disclosure: T. Johnson, None; J. Baker, Bristol-Myers Squibb, 2, 5, Burns-White LLC, 5; P. Roul, None; H. Sayles, None; G. Cannon, Amgen, 2; B. Sauer, Amgen, 2; T. Mikuls, BMS, 2, Horizon, 2; B. England, None.

To cite this abstract in AMA style:

Johnson T, Baker J, Roul P, Sayles H, Cannon G, Sauer B, Mikuls T, England B. Methotrexate Is Associated with Reduced Cardiovascular Risk in Rheumatoid Arthritis Independent of Disease Activity Modification [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/methotrexate-is-associated-with-reduced-cardiovascular-risk-in-rheumatoid-arthritis-independent-of-disease-activity-modification/. Accessed July 1, 2022.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/methotrexate-is-associated-with-reduced-cardiovascular-risk-in-rheumatoid-arthritis-independent-of-disease-activity-modification/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies